Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California. more
Time Frame | MNOV | Sector | S&P500 |
---|---|---|---|
1-Week Return | -10.26% | -2.27% | -0.57% |
1-Month Return | 5% | -3.96% | 1.21% |
3-Month Return | 15.38% | -9.7% | 7.57% |
6-Month Return | 53.28% | -3.37% | 11.45% |
1-Year Return | 32.91% | 3.71% | 28.48% |
3-Year Return | -29.29% | 3.8% | 29.52% |
5-Year Return | -72.11% | 39.78% | 90.66% |
10-Year Return | -39.48% | 106.91% | 203.75% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 4.00M | 4.04M | - | 1.00M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":99.07,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":24.77,"profit":true}] |
Cost of Revenue | 23.94K | 21.34K | - | 212.43K | 20.30K | [{"date":"2019-12-31","value":11.27,"profit":true},{"date":"2020-12-31","value":10.05,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":9.55,"profit":true}] |
Gross Profit | (23.94K) | (21.34K) | 4.04M | (212.43K) | 1.00M | [{"date":"2019-12-31","value":-0.59,"profit":false},{"date":"2020-12-31","value":-0.53,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-5.26,"profit":false},{"date":"2023-12-31","value":24.77,"profit":true}] |
Gross Margin | (Infinity%) | (0.53%) | 100.00% | (Infinity%) | 100.00% | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":-0.53,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 14.03M | 14.18M | 14.25M | 14.63M | 10.90M | [{"date":"2019-12-31","value":95.92,"profit":true},{"date":"2020-12-31","value":96.92,"profit":true},{"date":"2021-12-31","value":97.43,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":74.51,"profit":true}] |
Operating Income | (14.03M) | (14.18M) | (10.22M) | (14.63M) | (9.90M) | [{"date":"2019-12-31","value":-1403107700,"profit":false},{"date":"2020-12-31","value":-1417832300,"profit":false},{"date":"2021-12-31","value":-1021581200,"profit":false},{"date":"2022-12-31","value":-1462864900,"profit":false},{"date":"2023-12-31","value":-990026500,"profit":false}] |
Total Non-Operating Income/Expense | 2.25M | 683.96K | 227.75K | 1.37M | 3.17M | [{"date":"2019-12-31","value":71.07,"profit":true},{"date":"2020-12-31","value":21.6,"profit":true},{"date":"2021-12-31","value":7.19,"profit":true},{"date":"2022-12-31","value":43.33,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (12.93M) | (13.86M) | (10.13M) | (14.07M) | (8.57M) | [{"date":"2019-12-31","value":-1292899800,"profit":false},{"date":"2020-12-31","value":-1385554500,"profit":false},{"date":"2021-12-31","value":-1013168400,"profit":false},{"date":"2022-12-31","value":-1406626100,"profit":false},{"date":"2023-12-31","value":-856846900,"profit":false}] |
Income Taxes | 12.66K | (1.65K) | 2.57K | 2.82K | 3.05K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-13.02,"profit":false},{"date":"2021-12-31","value":20.28,"profit":true},{"date":"2022-12-31","value":22.29,"profit":true},{"date":"2023-12-31","value":24.07,"profit":true}] |
Income After Taxes | (12.94M) | (13.85M) | (10.13M) | (14.07M) | (8.57M) | [{"date":"2019-12-31","value":-1294165800,"profit":false},{"date":"2020-12-31","value":-1385389700,"profit":false},{"date":"2021-12-31","value":-1013425200,"profit":false},{"date":"2022-12-31","value":-1406908300,"profit":false},{"date":"2023-12-31","value":-857151600,"profit":false}] |
Income From Continuous Operations | (12.94M) | (13.85M) | (10.13M) | (14.07M) | (8.57M) | [{"date":"2019-12-31","value":-1294165800,"profit":false},{"date":"2020-12-31","value":-1385389700,"profit":false},{"date":"2021-12-31","value":-1013425200,"profit":false},{"date":"2022-12-31","value":-1406908300,"profit":false},{"date":"2023-12-31","value":-857151600,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (12.94M) | (13.85M) | (10.13M) | (14.07M) | (8.57M) | [{"date":"2019-12-31","value":-1294165800,"profit":false},{"date":"2020-12-31","value":-1385389700,"profit":false},{"date":"2021-12-31","value":-1013425200,"profit":false},{"date":"2022-12-31","value":-1406908300,"profit":false},{"date":"2023-12-31","value":-857151600,"profit":false}] |
EPS (Diluted) | (0.30) | (0.30) | (0.20) | (0.30) | (0.18) | [{"date":"2019-12-31","value":-30,"profit":false},{"date":"2020-12-31","value":-30,"profit":false},{"date":"2021-12-31","value":-20.4,"profit":false},{"date":"2022-12-31","value":-30.5,"profit":false},{"date":"2023-12-31","value":-18,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
MNOV | |
---|---|
Cash Ratio | 16.28 |
Current Ratio | 16.66 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MNOV | |
---|---|
ROA (LTM) | -9.51% |
ROE (LTM) | -13.32% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MNOV | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.05 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.95 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MNOV | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 106.43 |
P/B | 1.87 |
Price/FCF | NM |
EV/R | 38.74 |
EV/Ebitda | NM |
PEG | NM |
MediciNova Inc (MNOV) share price today is $2.1
Yes, Indians can buy shares of MediciNova Inc (MNOV) on Vested. To buy MediciNova Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MNOV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of MediciNova Inc (MNOV) via the Vested app. You can start investing in MediciNova Inc (MNOV) with a minimum investment of $1.
You can invest in shares of MediciNova Inc (MNOV) via Vested in three simple steps:
The 52-week high price of MediciNova Inc (MNOV) is $2.55. The 52-week low price of MediciNova Inc (MNOV) is $1.12.
The price-to-earnings (P/E) ratio of MediciNova Inc (MNOV) is
The price-to-book (P/B) ratio of MediciNova Inc (MNOV) is 1.87
The dividend yield of MediciNova Inc (MNOV) is 0.00%
The market capitalization of MediciNova Inc (MNOV) is $106.43M
The stock symbol (or ticker) of MediciNova Inc is MNOV